跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTIS2023-503429-20-00
CTIS2023-503429-20-00进行中（未招募）1 期

M24-209

Abbvie Deutschland GmbH & Co. KG0 个研究点目标入组 52 人开始时间: 2024年1月15日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
52
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+（—）
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

进行中（未招募）
1 期
ADP-TILIL7ocally advanced or metastatic melanomaMedDRA version: 21.1Level: PTClassification code: 10025670Term: Malignant melanoma stage III Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10025671Term: Malignant melanoma stage IV Class: 100000004864
CTIS2023-509665-20-00Herlev Hospital10
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaRelapsed or Refractory Multiple Myeloma (R/R MM)MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104
CTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55
进行中（未招募）
1 期
A study to learn about how much elinzanetant gets absorbed in the blood and how safe it is in healthy participants when taken as different types of formulationsVasomotor symptoms as a sex hormone-dependent disorder in women and menMedDRA version: 20.0Level: LLTClassification code: 10067819Term: Andropausal symptoms Class: 10014698MedDRA version: 21.0Level: LLTClassification code: 10020407Term: Hot flashes Class: 10047065MedDRA version: 21.1Level: PTClassification code: 10027304Term: Menopausal symptoms Class: 100000004872
CTIS2023-503968-16-00Bayer Consumer Care AG16
进行中（未招募）
1 期
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Multiple Myeloma
CTIS2024-512640-36-00AbbVie Deutschland GmbH & Co. KG6
进行中（未招募）
1 期
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expressionMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104
CTIS2023-507486-26-00Bayer Consumer Care AG135